Biomet was accused of paying bribes to healthcare providers in South America and China for business within their hospitals, violating the U.S. Foreign Corrupt Practices Act before Zimmer acquired the company. The company already agreed on a $17.3 million penalty payment and $5.4 million civil settlement, paid to the U.S. Securities and Exchange Commission, related to the case, according to Reuters.
Biomet initially reached a deferred prosecution agreement in 2012, but then breached the agreement in 2014. In the new settlement, Zimmer Biomet will pay $30.5 million and enter into a deferred prosecution agreement with the Department of Justice for three years.
As part of the new agreement, an independent compliance monitor will oversee the company focusing on the legacy Biomet operations that have been integrated into Zimmer Biomet.
Zimmer Biomet doesn’t expect the payment to affect its 2017 outlook, as the amounts paid were previously recorded in the company’s financial statements.
More articles on orthopedic devices:
8 orthopedic, spine device companies receive FDA 510(k) clearance in December
Amendia names Gary Maingot new EVP of operations
Providence Medical Technology names Gregory Curhan new CFO
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
